ConductScience.org, home

Trial · NCT00349973

Results by group32

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change in Positive Symptoms by Treatment AssignmentDipyridamoleBaseline - Somatic Concern2.222Standard Deviation 1.716units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineBaseline - Somatic Concern1.400Standard Deviation 0.548units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleFollow-Up - Somatic Concern1.60Standard Deviation 1.34units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineFollow-Up - Somatic Concern1.00Standard Deviation 0.00units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleBaseline - Conceptual Disorganization2.667Standard Deviation 1.225units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineBaseline - Conceptual Disorganization2.600Standard Deviation 0.894units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleFollow-Up - Conceptual Disorganization2.00Standard Deviation 1.41units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineFollow-Up - Conceptual Disorganization2.00Standard Deviation 1.41units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleBaseline - Hostility1.222Standard Deviation 0.667units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineBaseline - Hostility1.200Standard Deviation 0.447units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleFollow-Up - Hostility1.00Standard Deviation 0.00units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineFollow-Up - Hostility2.00Standard Deviation 1.41units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleBaseline - Suspiciousness4.11Standard Deviation 1.54units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineBaseline - Suspiciousness3.40Standard Deviation 1.82units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleFollow-Up - Suspiciousness3.000Standard Deviation 1.581units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineFollow-Up - Suspiciousness1.500Standard Deviation 0.707units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleBaseline - Hallucination2.67Standard Deviation 2.12units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineBaseline - Hallucination3.80Standard Deviation 1.30units on a scale
Change in Positive Symptoms by Treatment AssignmentDipyridamoleFollow-Up - Hallucination2.600Standard Deviation 2.191units on a scale
Change in Positive Symptoms by Treatment AssignmentOlanzapineFollow-Up - Hallucination2.500Standard Deviation 0.707units on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00349973/results